Viking Therapeutics’ VK2735 Shows Strong Weight-Loss Retention With Monthly Dosing

Viking Soars Alone as Obesity Complex Shrugs at Strong GLP-1 Results

Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data while every major obesity peer from Eli Lilly to Novo Nordisk barely registered a pulse, raising a pointed question about whether this catalyst belongs to Viking alone or signals something bigger.

Viking drug maintains up to 97% weight loss on less frequent dosing

Viking's VK2735 retained up to 97% of prior weight loss on every-other-week dosing and up to 90% monthly, versus 61% on placebo, in Sep 22, 2026 top-line data. · 19 sources across the spectrum on IJR News.

Viking Therapeutics’ VK2735 Shows Strong Weight-Loss Retention With Monthly Dosing

Viking Therapeutics (NASDAQ:VKTX) reported top-line results from a maintenance dosing study of VK2735, its dual GLP-1/GIP receptor agonist candidate for obesity, showing that participants retained much of their initial weight loss after transitioning from weekly treatment to every-other-week or mont

Viking Therapeutics' obesity drug shows durable weight-loss benefit ...

Viking Therapeutics VK2735 Obesity Drug Maintains Weight Loss Up to 97% as Shares Surge 40%

Viking Therapeutics said patients shifted to a less ‌frequent dosing regimen of its experimental obesity treatment showed superior weight loss maintenance to those on placebo, in a study, sending its shares up 40% before the bell.The company said on Tuesday that patients ⁠who switched to an every-other-week dosing of VK2735 maintained up to 97% of the weight they had lost during an initial 21-week treatment period, while ‌those on a monthly dosi…

Viking shares surge on updated obesity drug data

Trial participants mostly kept their weight down after switching from a weekly shot to less frequent dosing — findings that could strengthen Viking’s “competitive positioning,” one analyst wrote.